JOINT VENTURE WITH YAFO CAPITAL, LTD.
With the idea to have representatives for licensing transactions in Europe and in China, FCF Life Sciences formed a joint venture with Yafo Capital, Ltd. in 2019. Together, we form a unique team to address the needs of our European and Asian clients. Our aim is to facilitate and guarantee a smooth partnering process.
Facts on Yafo Capital, Ltd.
- Shanghai based advisory firm
- Established network and access to leading 200+ Pharma and MedTech companies in Asia
- Team of 20+ professionals with banking and healthcare background
- ~20 completed transactions within the last five years
ACCESS CHINA FORUM
Company presentations
0
Participants
0
Meeting requests
0
Assets presented
0
FCF co-organizes, together with its partner YAFO Capital, the “ACCESS CHINA Forum”, which will be held online 4x per year.
ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable business development opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations.
ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable business development opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations.
UPCOMING EVENT
FCF Robotics Venture Capital Report – 2024 published
September 10, 2024
FCF Fox Corporate Finance GmbH is pleased to publish the “Robotics Venture Capital Report – 2024”.
The report is part of the “FCF DeepTech Series”, which is a quarterly series of reports tracking European venture capital funding trends within four main DeepTech verticals.
Key findings are:
- VC Winter – The start-up robotics sector remains under pressure: After the peak in 2021 with €1.9bn in funding volume across 382 deals, the European start-up robotics sector has lost considerable in 2022 and especially in Q2 2023, hitting rock bottom in Q2 2024 (YTD) with €737m in funding across 130 transactions only. This underlines the ongoing uncertainty and the still present “VC Winter” in the sector
- Maturity phase – Increasing maturity of the VC robotics sector: While later-stage start-ups accounted for only 12% of the deals in 2019, this share has increased to 30% in 2024 (Q2 YTD). At the same time, the relative importance of early-stage investors such as angels, accelerators and early-stage VCs has decreased slightly from 68% to 65%, which indicates an increasing maturity of the companies in the market
- Mega-deals continue to dominate the financing volume: Since 2021, yearly total funding volumes were mainly driven by a few mega deals (>€100m), which reflects the continued selective willingness to invest in this sector:
- 2021 with CMR Surgical (€497m), Agile Robots (€184m, €107m), Skyports (€116m) and eCential Robotics (€100m) – 52% of total volume
- 2022 with Exotec (€295m) and Scandit (€132m) – 23% of total volume
- 2023 with Distalmotion (€142m) and CMR Surgical (€142m) – 20% of total volume
- 2024 with Skyports (€105m) and Medical Microinstruments (€102m) – 28% of total volume
- Germany as the flagship of the European start-up robotics industry: German robotics start-ups dominate the European Top 10 (measured by cumulative capital raised since 2019) as 3 out of the Top 10 Robotics companies are based in Germany: (i) Agile Robots (€322m, 3rd rank), (ii) NEURA Robotics (€182m, 7th rank), and (iii) Quantum Systems (€111m, 10th rank). This underlines Germany’s importance as a technological center for robotics innovation in Europe
- Weakened M&A market – exit opportunities limited: After the record years 2022 and 2023 with 11 and 12 transactions, respectively, the M&A market for Robotics start-ups has cooled down in 2024, with only 4 successful take-overs so far (Q2 YTD)
To access the full report, please click here.
By Florian Theyermann and Daniel Klier.
